Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial - Battelino, T; Bergenstal, RM; Rodriguez, A (Lancet Diabetes Endocrinol, 2022)
et al.